期刊
FRONTIERS IN ENDOCRINOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2021.679000
关键词
somatostatin receptor; pancreatic neuroendocrine tumor; somatostatin analog; peptide receptor radionuclide therapy; somatostatin receptor imaging
资金
- National Science Foundation of China [81871950, 81972250]
- Scientific Innovation Project of Shanghai Education Committee [2019-01-07-00-07-E00057]
- National Science Foundation for Distinguished Young Scholars of China [81625016]
- Shanghai Municipal Commission of Health and Family Planning [2018YQ06]
SSTRs have significant clinical significance in pNETs, serving as important targets for diagnosis and treatment, but further research is needed.
Pancreatic neuroendocrine tumors (pNETs) are rare and part of the diverse family of neuroendocrine neoplasms (NENs). Somatostatin receptors (SSTRs), which are widely expressed in NENs, are G-protein coupled receptors that can be activated by somatostatins or its synthetic analogs. Therefore, SSTRs have been widely researched as a diagnostic marker and therapeutic target in pNETs. A large number of studies have demonstrated the clinical significance of SSTRs in pNETs. In this review, relevant literature has been appraised to summarize the most recent empirical evidence addressing the clinical significance of SSTRs in pNETs. Overall, these studies have shown that SSTRs have great value in the diagnosis, treatment, and prognostic prediction of pNETs; however, further research is still necessary.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据